Restoration of tumor equilibrium after immunotherapy for advanced melanoma: Three illustrative cases

Melanoma Research

Volumn 21, Issue 2, 2011, Pages 152-159

  Wilgenhof, Sofie ^a,b   Pierret, Lauranne ^a   Corthals, Jurgen ^b   Van Nuffel, An M T ^b   Heirman, Carlo ^b   Roelandt, Truus ^a   De Coninck, Arlette ^a   Verfaillie, Guy ^a   Vandenbroucke, Frederik ^a   Van Riet, Ivan ^a   Bonehill, Aude ^b   Thielemans, Kris ^a,b   Neyns, Bart ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Cytotoxic T lymphocyte antigen 4; dendritic cell vaccine; equilibrium; immunotherapy; ipilimumab; melanoma

Indexed keywords

ALPHA2B INTERFERON; B RAF KINASE INHIBITOR; DACARBAZINE; DENDRITIC CELL VACCINE; FLUORODEOXYGLUCOSE F 18; IPILIMUMAB; LACTATE DEHYDROGENASE; TICILIMUMAB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONJUNCTIVITIS; DEPIGMENTATION; DERMATITIS; ELECTROPORATION; FEMALE; HUMAN; INFLAMMATORY INFILTRATE; INJECTION SITE REACTION; KIDNEY METASTASIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; LIVER RESECTION; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHOCYTE COUNT; MALE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; MUSCLE METASTASIS; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; PRIORITY JOURNAL; RETROPERITONEAL CANCER; SUBCUTANEOUS NODULE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; VISCERAL METASTASIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 79952984337     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328343ece0     Document Type: Article

References (34)

1. Balch C, Gershenwald J, Soong S, Thompson J, Atkins M, Byrd D, et al. Final Version of 2009 AJCC Melanoma Staging and Classification. J Clin Oncol 2009;27:6199-6206.
2. Thompson J, Scolyer R, Kefford R. Cutaneous melanoma. Lancet 365:687-701.
3. Garbe C, Eigentler T. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 2007;17:117-127. (Pubitemid 46673905)
4. Middleton M, Grob J, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-166. (Pubitemid 30036349)
5. Avril M, Aamdal S, Grob J, Hauschild A, Mohr P, Bonerandi J, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004;22:1118-1125. (Pubitemid 41095046)
6. Ives N, Stowe R, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2621 patients. J Clin Oncol 2007;25:5426-5434. (Pubitemid 350232219)
7. Atkins M, Lotze M, Dutcher J, Fisher R, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-2116. (Pubitemid 29318842)
8. Keilholz U. CTLA-4: negative regulator of the immune response and a target for cancer therapy. J Immunother 2008;31:431-439.
9. Rosenberg S, Yang J, Restifo N. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-915. (Pubitemid 39273730)
10. Atallah E, Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 2005;6:185-193. (Pubitemid 40945448)
11. Moschos S, Edington H, Land S, Rao U, Jukic D, Shipe-Spotloe J, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006;24:3164-3171. (Pubitemid 46638955)
12. Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006;106:1431-1442.
13. Eggermont A, Suciu S, Santinami M, Testori A, Kruit W, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372:117-126. (Pubitemid 351952257)
14. Kirkwood J, Tarhini A, Panelli M, Moschos S, Zarour H, Butterfield L, et al. Next generation of immunotherapy for melanoma. J Clin Oncol 2008;26:3445-3455.
15. Boon T, Coulie P, Van den Eynde B, Van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006;24:175-208.
16. Kantoff P, Higano C, Shore N, Berger E, Small E, Penson D, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-422.
17. Wolchok J, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-164.
18. Hodi F, O'Day S, McDermott D, Weber R, Sosman J, Haanen J, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
19. Tuma R. New response criteria proposed for immunotherapies. J Natl Cancer Inst 2008;100:1280-1281.
20. Wolchok J, Hoos A, O'Day S, Weber J, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-7420.
21. Van Baren N, Bonnet M, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005;23:9008-9021. (Pubitemid 46211485)
22. Kruit W, Van Ojik H, Brichard V, Escudier B, Dorval T, Dréno B, et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 2005;117:596-604. (Pubitemid 41504547)
23. Wilgenhof S, Van Nuffel AM, Benteyn D, Corthals J, Heirman C, Pierret L, et al. Clinical outcome following therapeutic vaccination with autologous mRNA electroporated dendritic cell (DC) vaccines in patients with advanced melanoma (Meeting Abstracts). J Clin Oncol 2010;28(15 Suppl):8547.
24. Dunn G, Bruce A, Ikeda H, Old L, Schreiber R. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998. (Pubitemid 35363648)
25. Koebel C, Vermi W, Swann J, Zerafa N, Rodig S, Old L, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903-907. (Pubitemid 350231320)
26. Teng M, Swann J, Koebel C, Schreiber R, Smyth M. Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol 2008;84:988-993.
27. Håkansson L. The capacity of the immune system to control cancer. Eur J Cancer 2009;45:2068-2070.
28. Mitchell M, Jakowatz J, Harel W, Dean G, Stevenson L, Boswell W, et al. Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. J Clin Oncol 1994;12:402-411. (Pubitemid 24056416)
29. Astsaturov I, Petrella T, Bagriacik E, de Benedette M, Uger R, Lumber G, et al. Amplification of virus-induced antimelanoma T-cell reactivity by highdose interferon-alpha2b: implications for cancer vaccines. Clin Cancer Res 2003;9:4347-4355. (Pubitemid 37248390)
30. Hodi F, Butler M, Oble D, Seiden M, Haluska F, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyteassociated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008;105:3005-3010. (Pubitemid 351723658)
31. Yuan J, Gnjatic S, Li H, Powel S, Gallardo H, Ritter E, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 2008;105:20410-20415.
32. Schwartzentruber DJ, Lawson D, Richards J, Conry RM, Miller D, Triesman J, et al. A phase III multi-institutional randomized study of immunization with the gp100:209-217 (210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma (Meeting Abstracts). J Clin Oncol 2009;27(18 S):CRA9011.
33. Messina J, Yu H, Riker A, Munster P, Jove R, Daud A. Activated stat-3 in melanoma. Cancer Control 2008;15:196-201.
34. Shah K, Chien A, Yee C, Moon R. CTLA-4 is a direct target of Wnt/betacatenin signaling and is expressed in human melanoma tumors. J Invest Dermatol 2008;128:2870-2879.